SGHT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

20.17M

+5.73%

-0.160

-30.39%

19.30M

+10.26%

-0.176

-37.21%

21.65M

+10.66%

-0.154

-32.94%

Estimates Revision

The market is revising Upward the revenue expectations for Sight Sciences, Inc. (SGHT) for FY2025, with the revenue forecasts being adjusted by 3.26% over the past three months. During the same period, the stock price has changed by 124.37%.

Revenue Estimates for FY2025

Revise Upward

+3.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-21.94%

In Past 3 Month

Stock Price

Go Up

+124.37%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast SGHT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is 5.17 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

5.17

High

7.00

Current: 0.000

Low

4.00

Averages

5.17

High

7.00

Piper Sandler

Matt O'Brien

Neutral -> Overweight

upgrade

2026-01-05

New

Reason

Piper Sandler

Matt O'Brien

Price Target

2026-01-05

New

upgrade

Neutral -> Overweight

Reason

Piper Sandler analyst Matt O'Brien upgraded Sight Sciences to Overweight from Neutral with a $9 price target.

Piper Sandler

Matt O'Brien

Neutral -> Overweight

upgrade

$5 -> $9

2026-01-05

New

Reason

Piper Sandler

Matt O'Brien

Price Target

$5 -> $9

2026-01-05

New

upgrade

Neutral -> Overweight

Reason

As previously reported, Piper Sandler analyst Matt O'Brien upgraded Sight Sciences to Overweight from Neutral with a price target of $9, up from $5. The firm has become increasingly bullish on the TearCare opportunity - though it would still advise some investor patience near-term as the company works to secure coverage from payors. Further, Piper says the company's surgical glaucoma business has performed better-than-expected in 2025 year-to-date and it sees brighter days ahead in FY26. While shares meaningfully outperformed in 2025, the firm thinks the risk-reward for Sight still skews positive at these levels.

UBS

Buy

upgrade

$7 -> $12

2025-12-23

Reason

UBS

Price Target

$7 -> $12

2025-12-23

upgrade

Buy

Reason

UBS raised the firm's price target on Sight Sciences to $12 from $7 and keeps a Buy rating on the shares. The firm is raising its price target as challenges diminish, the analyst tells investors in a research note.

UBS

NULL

Buy

upgrade

$7 -> $12

2025-12-22

Reason

UBS

Price Target

$7 -> $12

2025-12-22

upgrade

NULL

Buy

Reason

UBS raised the firm's price target on Sight Sciences to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative Contractors Novitas and First Coast Service Option established the Medicare fee schedule for TearCare, which represented a critical strategic milestone that increases market access for Sight Sciences' Dry Eye Solution, and the now-established $1,140 fee offers a clearer line of sight to accelerating TearCare utilization, expanding gross margins, and a potential inflection in revenue growth in 2026, the analyst tells investors in a research note.

Citi

Neutral -> Hold

upgrade

2025-12-11

Reason

Citi

Price Target

2025-12-11

upgrade

Neutral -> Hold

Reason

Citi raised the firm's price target on Sight Sciences to $9.10 from $5.50 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Lake Street

NULL -> Buy

upgrade

$7 -> $12

2025-12-10

Reason

Lake Street

Price Target

$7 -> $12

2025-12-10

upgrade

NULL -> Buy

Reason

Lake Street raised the firm's price target on Sight Sciences to $12 from $7 and keeps a Buy rating on the shares. The firm believes the setup for 2026 includes growth from both business segments and new coverage catalysts in the Dry Eye Disease business, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Sight Sciences Inc (SGHT.O) is -12.15, compared to its 5-year average forward P/E of -7.38. For a more detailed relative valuation and DCF analysis to assess Sight Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.38

Current PE

-12.15

Overvalued PE

-2.82

Undervalued PE

-11.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.71

Current EV/EBITDA

-19.39

Overvalued EV/EBITDA

0.32

Undervalued EV/EBITDA

-13.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.89

Current PS

4.75

Overvalued PS

11.63

Undervalued PS

0.14

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2970.96% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 2970.96% over the last month.

Sold

Bought

SGHT News & Events

Events Timeline

No data

News

6.0

2025-12-24Yahoo Finance

UBS Raises Sight Sciences Price Target to $12, Boosting Buy Rating

4.0

2025-11-11NASDAQ.COM

Sight Sciences (SGHT) Receives Upgrade to Buy: Key Information You Need to Know

9.5

2025-11-07NASDAQ.COM

Sight Sciences (SGHT) Q3 Earnings: Analyzing Key Metrics Against Expectations

People Also Watch

Frequently Asked Questions

What is Sight Sciences Inc (SGHT) stock price today?

The current price of SGHT is 7.18 USD — it has decreased -4.65 % in the last trading day.

What is Sight Sciences Inc (SGHT)'s business?

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

What is the price predicton of SGHT Stock?

What is Sight Sciences Inc (SGHT)'s revenue for the last quarter?

Sight Sciences Inc revenue for the last quarter amounts to 19.91M USD, decreased -1.25 % YoY.

What is Sight Sciences Inc (SGHT)'s earnings per share (EPS) for the last quarter?

Sight Sciences Inc. EPS for the last quarter amounts to -0.16 USD, decreased -27.27 % YoY.

What changes have occurred in the market's expectations for Sight Sciences Inc (SGHT)'s fundamentals?

How many employees does Sight Sciences Inc (SGHT). have?

Sight Sciences Inc (SGHT) has 216 emplpoyees as of January 10 2026.

What is Sight Sciences Inc (SGHT) market cap?

Today SGHT has the market capitalization of 379.62M USD.